Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients

BACKGROUND: Tumor Associated Antigens are characterized by spontaneous immune response in cancer patients as a consequence of overexpression and epitope-presentation on MHC class I/II machinery. Matrix Metalloprotease 11 (MMP11) expression has been associated with poor prognosis for several cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales: Roscilli, Giuseppe, Cappelletti, Manuela, De Vitis, Claudia, Ciliberto, Gennaro, Di Napoli, Arianna, Ruco, Luigi, Mancini, Rita, Aurisicchio, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936832/
https://www.ncbi.nlm.nih.gov/pubmed/24564996
http://dx.doi.org/10.1186/1479-5876-12-54
Descripción
Sumario:BACKGROUND: Tumor Associated Antigens are characterized by spontaneous immune response in cancer patients as a consequence of overexpression and epitope-presentation on MHC class I/II machinery. Matrix Metalloprotease 11 (MMP11) expression has been associated with poor prognosis for several cancer types, including breast and prostate cancer. METHODS: MMP11 expression was determined by immunoistochemistry in breast and prostate cancer samples. Circulating MMP11 protein as well as the spontaneous immune responses against MMP11 were analyzed in a set of breast and prostate cancer patients. RESULTS: In plasma samples MMP11 protein was present in 5/13 breast cancer patients and in 1/12 prostate cancer patients. An antibody response was observed in 7/13 breast cancer patients and in 3/12 prostate cancer patients. CONCLUSIONS: These findings further suggest MMP11 as a promising biomarker for these tumor types and a suitable target for cancer immunotherapy strategies.

Ejemplares similares